J Korean Med Assoc.  2013 Aug;56(8):711-717. 10.5124/jkma.2013.56.8.711.

Opioids use for chronic noncancer pain

• Hwang IC
• Shim JY

• KMID: 1847873
• DOI: http://doi.org/10.5124/jkma.2013.56.8.711

Abstract

The use of opioids for chronic noncancer pain has increased in recent years, although evidence for its long-term effectiveness is weak and its potential for harm is significant. Most reports suggest that chronic opioid therapy can be effective for the reduction of chronic pain and for the improvement of functioning and health-related quality of life. However, opioids are also associated with potentially serious harm including pharmacologic adverse effects and socioeconomic problems such as abuse, addiction, and diversion. Physicians should use a structured approach that includes a biopsychosocial evaluation and treatment plan that encourages patients to reach functional goals. There should be a comprehensive evaluation of the cause of pain, assessment for risk of opioid complications (including misuse and addiction), and a detailed treatment history including a review of medical records. Regular monitoring for safety and effectiveness is essential including regular checking of functional improvement and progress towards the pretreatment goals. Ineffective or unsafe opioid therapy should be promptly tapered or stopped. In Korea until now, there are no adequate recommendations for opioid prescription in the management of chronic noncancer pain. A Korean guideline or task force team should be established to provide personalized treatment for carefully selected and monitored patients.

Keyword

Opioid analgesics; Chronic pain; Addictive behavior

MeSH Terms

Advisory Committees
Analgesics, Opioid
Behavior, Addictive
Chronic Pain
Humans
Korea
Medical Records
Prescriptions
Quality of Life
Analgesics, Opioid

Figure

• 

  Figure 1 Stepped approach to opioid selection (From Canadian guideline for safe and effective use of opioids for chronic non-cancer pain [Internet]. Hamilton (ON): McMaster University; 2010, according to the Creative Commons license) [8].

Reference

1. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010; (1):CD006605.

2. Snidvongs S, Mehta V. Recent advances in opioid prescription for chronic non-cancer pain. Postgrad Med J. 2012; 88:66–72.

3. Jensen MK, Thomsen AB, Hojsted J. 10-Year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. Eur J Pain. 2006; 10:423–433.

4. Lee YW. Opioid therapy for chronic nonmaliganat pain. Hanyang Med Rev. 2011; 31:70–75.

5. Kwak KS, Chun SH, Lee KH, Ha JO. Analysis of the perception of hospice and narcotic analgesics by family caregivers of terminal cancer patient. Korean J Hosp Palliat Care. 2006; 9:106–111.

6. Yoo YS, Choe SO, Cho YY, Koh SJ, Hor SJ, Jeon J, Kwon SH. Patient-related barriers to pain management in general population. Korean J Hosp Palliat Care. 2007; 10:184–189.

7. Manchikanti L, Ailinani H, Koyyalagunta D, Datta S, Singh V, Eriator I, Sehgal N, Shah R, Benyamin R, Vallejo R, Fellows B, Christo PJ. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician. 2011; 14:91–121.

8. National Opioid Use Guide Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain [Internet]. Hamilton (ON): McMaster University;2010. cited 2013 May 6. Available from: http://nationalpaincentre.mcmaster.ca/opioid/.

9. Siddall PJ, Cousins MJ. Persistent pain as a disease entity: implications for clinical management. Anesth Analg. 2004; 99:510–520.

10. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10:287–333.

11. Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch JA. American Society of Interventional Pain Physicians. Comprehensive review of epidemiology, scope, and impact of spinal pain. Pain Physician. 2009; 12:E35–E70.

12. Lee JS, Jeong DU. Sleep and pain. Sleep Med Psychophysiol. 2012; 19:63–67.

13. Park JC, Choi YS, Kim JH. Current pharmacological management of chronic pain. J Korean Med Assoc. 2010; 53:815–823.

14. Kindler LL, Sibille KT, Glover TL, Staud R, Riley JL 3rd, Fillingim RB. Drug response profiles to experimental pain are opioid and pain modality specific. J Pain. 2011; 12:340–351.

15. Sohn KS, Kim JH. Recent trends in pharmacologic treatment of cancer pain. J Korean Med Assoc. 2012; 55:666–675.

16. Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract. 2009; 9:468–479.

17. Vissers KC, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract. 2010; 10:85–93.

18. Berland D, Rodgers P. Rational use of opioids for management of chronic nonterminal pain. Am Fam Physician. 2012; 86:252–258.

19. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009; 10:131–146.

20. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA. 1995; 274:1870–1873.

21. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995; 63:65–76.

22. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996; 347:143–147.

23. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 2011; 30:264–270.

24. Whelan E, Asbridge M, Haydt S. Representations of OxyContin in North American newspapers and medical journals. Pain Res Manag. 2011; 16:252–258.

25. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers: United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011; 60:1487–1492.

26. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician. 2012; 15:3 Suppl. ES191–ES203.

27. Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. Addiction. 2013; 108:688–698.

28. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007; 129:235–255.

29. Substance Abuse & Mental Health Services Administration. National Survey on Drug Use and Health: detailed tables 6.47 and 6.48 [Internet]. Rockville (MD): SAMHSA;2009. cited 2013 Jul 10. Available from: http://oas.samhsa.gov/NSDUH/2k9NSDUH/tabs/Sect6peTabs1to54.htm#Tab6.48A.

30. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012; 31:207–225.

31. Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011; 37:205–217.

32. Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006; 9:57–60.